More evidence of no survival benefit in COVID-19 patients receiving hydroxychloroquine

7-Jun-2020 11:35 PM EDT, by Cell Press

Newswise — A study of electronic medical records from US Veterans Health Administration medical centers has found that hydroxychloroquine--with or without azithromycin--did not reduce the risk of ventilation or death and was associated with longer length of hospital stay. This analysis, published June 5 in the journal Med, is the first in the US to report data on hydroxychloroquine outcomes for COVID-19 from a nationwide integrated health system.

The study included data from 807 people hospitalized with COVID-19 at Veterans Affairs medical centers around the country. About half, 395 patients, did not receive hydroxychloroquine at any time during their hospitalization. Among those who did, 198 patients were treated with hydroxychloroquine and 214 were treated with both hydroxychloroquine and azithromycin. Most of the patients given hydroxychloroquine, about 86%, received it before being put on a mechanical ventilator.

After adjustment for clinical characteristics, the risk of death from any cause was higher in the hydroxychloroquine group but not in the hydroxychloroquine + azithromycin group when these were compared with the no-hydroxychloroquine group. The researchers also found that the length of hospital stay was 33% longer in the hydroxychloroquine group and 38% longer in the hydroxychloroquine + azithromycin group than in the no-hydroxychloroquine group. Pre-existing conditions such as cardiovascular disease, chronic obstructive pulmonary disease, and diabetes were relatively common and similar across all groups.

The researchers--from the Columbia VA Health Care System, the University of South Carolina, and the University of Virginia School of Medicine--reported that their study has strengths that earlier studies have not had. For example, because it employed data from comprehensive electronic medical records (the VA Informatics and Computing Infrastructure, or VINCI), rather than administrative health insurance claims, they were able to apply rigorously identified covariates and outcomes. Additionally, because the data came from an integrated national healthcare system, the findings were less susceptible to biases that might occur in a single-center or regional study.

But they also acknowledge limitations: the median age in their study was about the same age as that in other studies of hospitalized patients, 70 years, but because the patients were older the findings might not apply to younger people with COVID-19, although a quarter of patients ranged from 22 to 60 years old. Additionally, the patients in the study were overwhelmingly male, nearly 96%, reflecting the demographics of veterans. The researchers also note that the findings don't provide insight into the use of these drugs in the outpatient setting or as prophylaxis, but they add that the FDA and the U.S. National Institutes of Health have both advised against the use of hydroxychloroquine outside of clinical trials.

###

No funding agency had a role in study design or conduct, data collection, analysis, interpretation, or manuscript writing.

Med, Magagnoli, Narendran, and Pereira et al. "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19" https://www.cell.com/med/fulltext/S2666-6340(20)30006-4

Cell Press Coronavirus Resource Hub: https://www.cell.com/COVID-19

Med (@MedCellPress), a new journal from Cell Press, publishes transformative, evidence-based science offering novel insights in disease understanding across the clinical and translational research continuum--from large-scale clinical trials to studies with demonstrable functional impact. Visit: https://www.cell.com/med. To receive Cell Press media alerts, please contact press@cell.com.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 2813
Newswise: 239458_web.jpg
Released: 5-Aug-2020 2:50 PM EDT
New findings on enzymes with important role in SARS-CoV-2 infection
Uppsala University

Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.

Newswise: Button Project Lets Children See the Faces Behind the Masks
Released: 5-Aug-2020 2:50 PM EDT
Button Project Lets Children See the Faces Behind the Masks
Vanderbilt University Medical Center

When COVID-19 cases began rising in Nashville, masking became a regular part of life across Vanderbilt University Medical Center and Children’s Hospital as one of several public health safety measures to protect employees and patients from potential COVID-19 exposure. Children’s Hospital decided to get creative to ensure that the 1,700 children and families who visit the hospital and clinics each day can see that the same friendly faces they’ve always known still exist behind the masks.

Newswise: 239490_web.jpg
Released: 5-Aug-2020 1:45 PM EDT
Massey scientist suggests COVID-19 should be treated as an acute inflammatory disease
Virginia Commonwealth University (VCU)

The COVID-19 pandemic has had detrimental effects on global infrastructure sectors, including economic, political, health care, education and research systems, and there is still no definitive treatment strategy for the disease.

Newswise: Helping protect medical professionals
Released: 5-Aug-2020 1:05 PM EDT
Helping protect medical professionals
Sandia National Laboratories

A media comprised of a sandwich of materials, tested by Sandia National Laboratories, is being manufactured into N95-like respirators that could be used in local medical facilities. The project originated from the urgent need for personal protective equipment when the COVID-19 outbreak began.

Released: 5-Aug-2020 12:50 PM EDT
UCI scientists get ‘initial hit’ in developing drug to treat COVID-19
University of California, Irvine

Irvine, Calif., Aug. 5, 2020 – When the coronavirus pandemic hit, almost everyone at the University of California, Irvine – and colleges across the nation – had to abandon campus. But James Nowick, professor of chemistry, was not a part of that exodus. That’s because his lab, which designs and constructs chemical molecules, had the right equipment to help in the global push to find treatments for COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 6-Aug-2020 11:00 AM EDT Released to reporters: 5-Aug-2020 12:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 6-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Imitation May Be a Sincere Form of Treatment
Released: 5-Aug-2020 12:35 PM EDT
Imitation May Be a Sincere Form of Treatment
University of California San Diego Health

The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.

Newswise: NIH harnesses AI for COVID-19 diagnosis, treatment, and monitoring
Released: 5-Aug-2020 12:30 PM EDT
NIH harnesses AI for COVID-19 diagnosis, treatment, and monitoring
National Institute of Biomedical Imaging and Bioengineering

NIH has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.


Showing results

110 of 2813

close
2.04558